Patents by Inventor John P. Vaillancourt

John P. Vaillancourt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA encoding precursor of interleukin-1.beta. converting enzyme--related cysteine proteinase II (ICE.sub.rel -II)
    Patent number: 6110701
    Abstract: A complementary DNA (cDNA) encoding full length form of ICE.sub.rel -II is identified, sequenced and isolated. The cDNA is cloned into expression vectors for expression in recombinant hosts. The cDNA is useful to produce recombinant full length ICE.sub.rel -II. The cDNA and the recombinant ICE.sub.rel -II protein derived therefrom are useful in diagnostic kits, laboratory reagents and assays. The cDNA and the recombinant ICE.sub.rel -II protein may be used to identify compounds that affect ICE.sub.rel -II function, inflammation and cell apoptosis. ICE.sub.rel -II function, inflammation and cell apoptosis may also be modulated by ICE.sub.rel -II antisense or gene therapy.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: August 29, 2000
    Assignee: Merck Frosst Canada & Co.
    Inventors: Donald W. Nicholson, Ambereen Ali, Neil A. Munday, John P. Vaillancourt
  • Interleukin-1.beta. converting enzyme-related cysteine proteinase II (ICE.sub.rel -II)
    Patent number: 6103513
    Abstract: A complementary DNA (cDNA) encoding full length form of ICE.sub.rel -II is identified, sequenced and isolated. The cDNA is cloned into expression vectors for expression in recombinant hosts. The cDNA is useful to produce recombinant full length ICE.sub.rel -II. The cDNA and the recombinant ICE.sub.rel -II protein derived therefrom are useful in diagnostic kits, laboratory reagents and assays. The cDNA and the recombinant ICE.sub.rel -II protein may be used to identify compounds that affect ICE.sub.rel -II function, inflammation and cell apoptosis. ICE.sub.rel -II function, inflammation and cell apoptosis may also be modulated by ICE.sub.rel -II antisense or gene therapy.
    Type: Grant
    Filed: February 10, 1997
    Date of Patent: August 15, 2000
    Assignee: Merck Frosst Canada & Co.
    Inventors: Donald W. Nicholson, Ambereen Ali, Neil A. Munday, John P. Vaillancourt
  • Method for identifying inhibitors for apopain based upon the crystal structure of the apopain: Ac-DEVD-CHO complex
    Patent number: 5834228
    Abstract: The apopain:Ac-DEVD-CHO complex has been crystallized and its structure determined by x-ray crystallography. Based upon this crystal structure of the complex, a method for identifying inhibitors of apopain is presented which comprises designing putative inhibitors having specific contacts with apopain, making the putative inhibitors, and testing the putative inhibitors for their ability to inhibit apopain.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: November 10, 1998
    Assignees: Merck & Co., Inc., Merck Frosst Canada, Inc.
    Inventors: Joseph W. Becker, Donald W. Nicholson, Jennifer Rotonda, Nancy A. Thornberry, Kimberly M. Fazil, Michel Gallant, Yves Gareau, Marc Labelle, Erin P. Peterson, Dita M. Rasper, Rejean Ruel, John P. Vaillancourt
  • DNA encoding precursor of interleukin-1.beta. converting enzyme-related cysteine proteinase III (ICE.sub.rel -III)
    Patent number: 5760180
    Abstract: A complementary DNA (cDNA) encoding full length form of ICE.sub.rel -III is identified, sequenced and isolated. The cDNA is cloned into expression vectors for expression in recombinant hosts. The cDNA is useful to produce recombinant full length ICE.sub.rel -III. The cDNA and the recombinant ICE.sub.rel -III protein derived therefrom are useful in diagnostic kits, laboratory reagents and assays. The cDNA and the recombinant ICE.sub.rel -III protein may be used to identify compounds that affect ICE.sub.rel -III function, inflammation and cell apoptosis. ICE.sub.rel -III function, inflammation and cell apoptosis may also be modulated by ICE.sub.rel -III antisense or gene therapy.
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: June 2, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Donald W. Nicholson, Ambereen Ali, Neil A. Munday, John P. Vaillancourt
  • DNA encoding precursor of interleukin-1 beta converting enzyme - related cysteine proteinase III (ice rel-III)
    Patent number: 5552536
    Abstract: A complementary DNA (cDNA) encoding full length form of ICE.sub.rel -III is identified, sequenced and isolated. The cDNA is cloned into expression vectors for expression in recombinant hosts. The cDNA is useful to produce recombinant full length ICE.sub.rel -III. The cDNA and the recombinant ICE.sub.rel -III protein derived therefrom are useful in diagnostic kits, laboratory reagents and assays. The cDNA and the recombinant ICE.sub.rel -III protein may be used to identify compounds that affect ICE.sub.rel -III function, inflammation and cell apoptosis. ICE.sub.rel -III function, inflammation and cell apoptosis may also be modulated by ICE.sub.rel -III antisense or gene therapy.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: September 3, 1996
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Donald W. Nicholson, Ambereen Ali, Neil A. Munday, John P. Vaillancourt